Published Date : Apr 18, 2017
ALBANY, New York, April 18, 2017: MarketResearchReports.biz has added a new market study to its repository, titled, “EpiCast Report: Bladder Cancer - Epidemiology Forecast to 2025.” By furnishing relevant information on bladder cancer and its therapeutics market, the report attempts to help savvy players in the domain to develop astute business strategies, products, and prices to cater to patient groups with various needs.
Bladder cancer claims quite a few lives worldwide, annually. It results from smoking and occupational risk factors such as exposure to aromatic amines. These risk factors tend to affect men more than women. Hence, the incidence of bladder cancer is higher amongst men than in women. Further, those aged 73 and above are more susceptible to bladder cancer. The report begins with an epidemiology and then progresses to study the disease background
Having discussed in-depth about bladder cancer, the report goes on to present statistics pertaining the number of patients in different age groups, sexes, and stages of the disease. As per epidemiologists’ forecasts, the seven major markets of the U.S., France, Germany, Italy, Spain, the U.K., and Japan are predicted to have 289,623 diagnosed cases of bladder cancer by 2025. This would represent a rise of 23.5% from the 234,581 cases in 2015.
In 2015, the seven major markets had 873,493 cases of five-year diagnosed bladder cancer. Moving ahead, the number is predicted to reach 1,094,707 by clocking an Annual Growth Rate (AGR) of 2.53%. The report also offers figures on cancer stage depending upon diagnosis such as stage 0, stage I, stage II, stage III, and stage IV.
For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/915866
North America and Europe are considered key markets for bladder cancer treatment drugs because of the presence of advanced health care solutions, increase in bladder cancer cases, and rising concern about bladder problems. In the next couple of years, however, Asia Pacific is predicted to expand substantially on account of the spike in instances of bladder cancer which would necessitate better treatments and therapies. Other factors that will likely stoke market growth in the region are growth in healthcare expenditure and improving healthcare infrastructure.
Some of the noticeable trends in the bladder cancer diagnostics market are the rise in the number of mergers and acquisitions and collaborations and partnerships. New product launches are also commonplace in the market that is increasingly investing in research and development for breakthrough treatments.
Some of the prominent names operating in the global market for bladder cancer treatment drugs are GlaxoSmithKline plc, Novartis International AG, Pfizer Inc., Sanofi S.A., Eli Lilly and Co, AstraZeneca plc, Bristol-Myers Squibb, and F. Hoffmann-La Roche AG.
To order report Call Toll Free: 866-997-4948 or send an email on email@example.com